Back

Acute procedural characteristics and safety of pulsed field cryoablation for persistent AF: multicenter results from the first in human PARALELL trial

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Arrhythmias 4 Catheter Ablation of Arrhythmias EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Vidal Essebag

McGill University Health Centre, Montreal (Canada)

8 More presentations in this session

Presentation thumbnail
Post-ablation atrial arrhythmogenic channels predict atrial fibrillation recurrence - iatrogenic substrate revisited
Doctor T. Althoff (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Heart rate from intermittent home measurements within an atrial fibrillation screening program is associated with mortality
Miss R. Van Der Velden (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
First-time catheter ablation outcomes for atrial fibrillation are dependent on low-voltage areas rather than paroxysmal vs. persistent classifications: a REAL-AF study
Mr A. Nguyen (Los Angeles, US)
Abstract Slides Video
Presentation thumbnail
Comparison of pulsed field and radiofrequency ablation for non-paroxysmal atrial fibrillation: a propensity score-matched analysis
Doctor V. Sousonis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Quantifying local cardiac substrate heterogeneity from high density recordings: an experimental study
Mr S. Ruiperez-Campillo (Zurich, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias 4

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
Impact of ablation modality on alternative efficacy endpoint definition of pulmonary vein isolation for atrial fibrillation
thumbnail
Congress Presentation
Pulsed-field ablation versus cryoballoon ablation in patients with persistent atrial fibrillation undergoing first catheter ablation
thumbnail
Congress Presentation
Direct comparison of two commercially available pulsed field ablation systems for atrial fibrillation; procedure characteristics and acute outcomes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources